This Phase II trial evaluated the efficacy of bendamustine, bortezomib and rituximab in patients with previously untreated low-grade lymphoma. Eligible patients had low grade lymphoma with no previous systemic disease treatment. Treatment for all patients was given in 28-day cycles for a maximum of 6 cycles. Patients received rituximab 375 mg/m 2 intravenously (IV) on days 1, 8 and 15 of cycle 1 and day 1 of cycles 2-6; bendamustine 90 mg/m 2 IV on days 1 and 2; and bortezomib 1Á6 mg/m 2 IV on days 1, 8
Bendamustine is a bi-functional anti-neoplastic agent with both a purine-like benzimidazole ring and alkylating group. It has demonstrated clinical activity in patients with advanced indolent non-Hodgkin lymphoma (NHL) (Heider & Niederle, 2001; Bremer, 2002; Friedberg et al, 2008; Kahl et al, 2010) . In a multicentre, phase II study of patients with relapsed, rituximab-refractory NHL, single-agent bendamustine resulted in an overall response rate (ORR) of 77% with 34% complete responses (CRs); median duration of response was 6Á7 months (Friedberg et al, 2008) .
The monoclonal antibody rituximab is active against most CD20+ B-cell malignancies. Rituximab, in combination with standard chemotherapy regimens, such as the combination of cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone (CHOP) or cyclophosphamide, vincristine sulfate and prednisone (CVP), has improved response rates and survival when used for indolent NHL and diffuse large B-cell lymphoma (Hiddemann et al, 2005; Marcus et al, 2005) .
The combination of bendamustine and rituximab (BR) has been shown to be as effective or superior to R-CHOP in low-grade and mantle cell lymphoma (Rummel et al, 2005; Flinn et al, 2014) . In the BRIGHT randomised trial, BR was compared to rituximab + CHOP (R-CHOP) or rituximab + CVP (R-CVP) in 447 patients with previously untreated low grade or mantle cell lymphoma. The CR rate was 31% with BR compared to 25% with R-CHOP/R-CVP (Flinn et al, 2014) . In the Study Group for Indolent Lymphoma (STiL) trial comparing BR to R-CHOP, median progression-free survival (PFS) was 69Á5 months for patients treated with BR compared to 31Á2 months for patients on R-CHOP (Rummel et al, 2013) . The overall response for both treatment groups was 93%. The CR rate was 40% for patients treated with BR compared to 30% for patients on R-CHOP (P = 0Á021) (Rummel et al, 2013) .
Bortezomib is a reversible 26S proteasome inhibitor that is approved for the treatment of multiple myeloma and mantle cell lymphoma. It has been shown to have significant activity in a broad array of patients with NHL (Goy et al, 2005; O'Connor et al, 2005; Strauss et al, 2006) . In follicular lymphoma, bortezomib improved the median PFS from 11Á0 to 12Á8 months in patients with relapsed disease (Coiffier et al, 2011) when added to rituximab. Given this data, the combination of all three agents (bendamustine, bortezomib and rituximab [BBR] ) was evaluated in patients with relapsed/refractory indolent NHL and mantle cell lymphoma with promising results. In a heavily pre-treated population a 2-year PFS of 47% was noted (Friedberg et al, 2011) . Similarly, the VERTICAL study examined the efficacy of BBR for patients with relapsed/refractory follicular lymphoma. Patients had an ORR of 88% and median PFS of 19Á9 months (Strauss et al, 2006) . In both studies, myelosuppression and neuropathy were significant adverse events (Fowler et al, 2011; Friedberg et al, 2011) .
Given the promising results of BBR in relapsed lymphoma, we sought to evaluate this regimen in patients with previously untreated, low grade lymphoma.
Patient and methods

Eligibility criteria
This study (ClinicalTrials.gov number: NCT01029730), was a single arm, multicentre phase II trial. The study was approved by the Institutional Review Boards of participating sites and patients were enrolled following written informed consent. Eligible patients had symptomatic histologically-confirmed, previously untreated indolent lymphoma (follicular lymphoma [grade 1 or 2], marginal zone lymphoma, small lymphoblastic lymphoma or lymphoplasmacytic lymphoma) that was Ann Arbor stage II-IV. Enrolled patients had a CD20+ B-cell positive lymph node biopsy, at least 1 measurable lesion ≥2 cm in a single dimension, Eastern Cooperative Oncology Group (ECOG) performance status of ≤2, and were ≥18 years of age, with adequate renal and hepatic function. Exclusion criteria included chronic lymphocytic leukaemia (CLL), transformed lymphoma, previous systemic treatment for lymphoma, including administration of corticosteroids, or ≥Grade 2 peripheral neuropathy.
Study design and treatment
Prior to trial entry, all patients underwent an evaluation which included physical examination, Ann Arbor staging, computed tomography or magnetic resonance imaging of the chest, neck, abdomen and pelvis; bone marrow aspirate/ biopsy; complete blood count, including differentials and platelet count; International Normalised Ratio and complete blood chemistry, including creatinine. Creatinine clearance was measured using the Cockcroft-Gault formula (Cockcroft & Gault, 1976) . Patients completed a neurotoxicity questionnaire at baseline and prior to each bortezomib dose throughout the study.
All patients received 6 cycles of intravenous (IV) infusions of rituximab (Cycle 1 org/practice-guidelines/quality-guidelines/ guidelines/supportive-care-and-treatment-related-issues) at the discretion of the investigator. Growth factors, including granulocyte-colony stimulating factor and granulocytemacrophage colony stimulating factor, were also permitted. Up to two dose reductions were allowed if the patient experienced toxicity. For patients that experienced multiple toxicities, dose adjustments were made based on the most severe toxicity. If more than two dose reductions for a study drug were required, the patient discontinued the drug, but continued with the other drugs in the treatment combination.
Patients were evaluated for response at the end of Cycles 3 and 6. Patients then had the option to continue additional maintenance rituximab treatment. Maintenance schedules varied according to preference of treating physician. Patients were monitored every 3 months for the first year and then every 6 months, until disease progression. Response assessments were performed according the International Working Group and Waldenstrom criteria (Weber et al, 2003; Cheson et al, 2007) .
Safety assessments
All patients who received at least one dose of protocol treatment were followed for toxicity. All adverse events (AEs), regardless of relationship to study medication, were collected from the first dose to 30 days after the last dose of study medication. Serious adverse events (SAEs) were collected until the end of study or the start of subsequent anti-cancer therapy. Toxicities were graded according to the National Cancer Institute's (NCI) Common Terminology for Adverse Events (CTCAE) version 4.0 (https://evs.nci.nih. gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_ 5x7.pdf). Patients were further assessed for neuropathy using the Functional Assessment of Cancer Therapy (FACT/ GOG)-Neurotoxicity Questionnaire, V 4.0 (Cella et al, 1993) .
Efficacy assessments
The primary endpoint of this study was the CR rate. Secondary endpoints included estimation of PFS.
Statistical analysis
The study required up to 55 patients. This accrual total included adjustment for up to a 10% unevaluable rate. The primary outcome variable for this trial was CR rate. A sample size of 50 achieves 81% power to detect a 33% increase in the estimated population CR rate of 0Á47 (Rummel et al, 2007 ) using a one-sided binomial test. The alpha level is 0Á10. These results assume that the population proportion under the null hypothesis is 0Á47. It was projected that the addition of bortezomib to bendamustine and rituximab would improve the CR rate from 47% to 63%. The sample size/power calculation was performed using PASS 2008 (Hintze, 2008) and methods consistent with Chow et al (2008) . The treated and the safety populations were both defined as all patients who received at least one dose of any study drugs. The primary endpoint of this study was the CR rate prior to beginning maintenance rituximab. Patients who discontinued the study prior to their post-baseline assessment were considered unevaluable for response. Secondary endpoints include estimation of PFS, defined as the interval of time between the date of the first administration of study treatment and the earlier of the date of disease progression and the date of death due to any cause. Analysis for PFS was summarized using the Kaplan-Meier estimates.
Results
Patient characteristics
Between March 2010 and October 2011, 55 patients were accrued and 54 patients were treated on this study. One patient was ineligible and excluded from this report. All patients had low grade lymphomas including 37 (69%) patients with follicular lymphoma, 8 patients (15%) with marginal zone lymphoma, 5 patients (9%) with small cell lymphoma, and 4 patients (7%) with lymphoplasmacytic lymphoma. A summary of baseline patient characteristics is found in Table I . In brief, patients were 52% male, 96% Caucasian, and the majority were Ann Arbor stage III or IV (87%) at the time of diagnosis. There were 37 patients (69%) with follicular lymphoma. Thirteen patients (35%) 
Patient disposition
Of the 54 eligible patients enrolled in the study, 44 (81%) received all 6 cycles of study treatment, with a median of 6 (range 1-6). The median number of cycles given at full dose intensity was 4 (range 1-6). Ten (19%) patients discontinued prior to completing 6 cycles. Six patients (11%) discontinued treatment due to toxicity (Grade 2 peripheral neuropathy . Two patients discontinued due to either physician or patient request. One patient discontinued due to intercurrent illness (herpes simplex virus and E. coli infection). One patient died on study of an embolic stroke determined to be unrelated to treatment. Thirty seven of the 44 patients that completed all 6 cycles of treatment started maintenance therapy with rituximab after response evaluation. Of these 37 patients that started the maintenance rituximab, 27 completed this portion of the study and ten patients discontinued prior to completion of maintenance treatment. Three patients (6%) discontinued maintenance rituximab due to disease progression, three patients (6%) discontinued due to patient request, one (2%) was lost to follow-up, one (2%) lost insurance, one (2%) discontinued due to intercurrent illness (pelvic abscess) and one (2%) died during the maintenance portion of the study (death, cause not specified). Throughout the study, there were 18 bortezomib dose reductions in 15 patients, and 10 bendamustine dose reductions in eight patients that were due to AEs (Table II) .
Safety
There were no unexpected AEs and the nature and severity of the AEs and SAEs were consistent with the known safety profile of bendamustine, bortezomib and rituximab. The most frequent AEs (Table IIIA) were fatigue (87%), nausea/ vomiting (69%), thrombocytopenia (61%), leucopenia (52%) and peripheral neuropathy (52%). The most common treatment-related Grade 3/4 AEs were leucopenia (28%), neutropenia (30%) lymphopenia (17%) and peripheral neuropathy (9%). Eleven patients (20%) had a treatmentrelated SAE during the study. There were 6 AEs related to infections during the study, including a case of herpes zoster, *Unevaluable patients came off study prior to their second disease assessment (1 patient death due to an unrelated embolic stroke, 2 patients due to toxicity and 1 patient requested to withdraw from the study).
a skin infection, a peri-sigmoid abscess, a pelvic infection, soft-tissue infection and a staphylococcal infection (Table IIIB) . There were no treatment-related deaths. One patient died during treatment of an unrelated embolic stroke. One additional patient died during maintenance treatment (death, cause not specified).
Efficacy
The ORR was 94% overall and 94% for the follicular lymphoma population (Table IV) . The CR rate was 64%, partial response was 30%, stable disease was 4% and disease progression was 2% overall. The observed CR rate of 64% allows for the rejection of the null hypothesis (CR rate of 47%) at the 0Á10 significance level. For patients with follicular lymphoma, the CR rate was 66%, partial response was 29%, stable disease was 3% and disease progression was 3%.
The median follow-up was 54 months (range 0Á7-75 months). The 36-month PFS probability was 75% (95% confidence interval [CI]: 60%, 85%) for all patients and 72% for patients with follicular lymphoma (95% CI: 53%, 84%) (Fig 1) . Median overall survival (OS) has not been reached. The 36-month OS probability was 88% (95% CI: 75%, 95%) for all patients and 88% for patients with follicular lymphoma (95% CI: 72%, 96%) (Fig 2) .
Discussion
The combination of bendamustine, bortezomib and rituximab (BBR) produced deep and durable remissions with an acceptable safety profile in patients with previously untreated, low grade lymphoma. PFS was durable at 36 months where 75% of patients have not progressed.
The BBR drug combination produced high CR rates which compare favourably to a recent Phase III trial using bendamustine plus rituximab (Flinn et al, 2014) . It should be noted that this study was a Phase II trial and used investigator assessments rather than central review, as used in the Phase III BRIGHT trial (Flinn et al, 2014) . However, important patient characteristics in this trial, including stage and FLIPI scores, were similar to patients in the BRIGHT study (Flinn et al, 2014) . The overall response rates were comparable to the BRIGHT study with a 94% ORR in this study, compared to 97% ORR in the BRIGHT study (Flinn et al, 2014) . However, the first-line treatment regimen used in this study provided a CR rate of 64% for all indolent NHL patients and 66% for patients with follicular lymphoma. The BRIGHT study reported CR rates of 28% and 30%, respectively, for indolent and follicular lymphoma patients treated with bendamustine plus rituximab (Flinn et al, 2014) . The STiL trial, comparing BR to R-CHOP (Rummel et al, 2013) , used investigator assessments, similar to the assessment methods used for this study. The BBR regimen of this report compares favourably with the 40% CR rate noted in the StiL trial. With a median follow-up of 45 months, patients treated with BR on the STiL trial had a median PFS of 69Á5 months (Rummel et al, 2013) . With a median follow up of 54 months, the median PFS has not been reached for the present study and the 36-month PFS was 75%. There were no unforeseen toxicities noted with this population. Neuropathy was a concern before initiating the trial, thus a neuropathy tool (Cella et al, 1993) was used to increase sensitivity of capturing this event. The use of this questionnaire may have resulted in higher neurotoxicity events reported in this study compared to studies that did not use this approach. However, neurotoxicity was only mildly worse than seen with R-CVP or R-CHOP in the BRIGHT study (Flinn et al, 2014) . One reason for the significant neuropathy rate seen in this study may be the method of bortezomib administration employed. It is possible that the neuropathy rate could be reduced by subcutaneous administration of bortezomib compared to IV bortezomib, as is seen in multiple myeloma (Moreau et al, 2011) .
Novel agents are needed for the treatment of indolent NHLs in general, and follicular lymphoma in particular, but the search is challenging. The PI3K inhibitor, idelalisib, has shown promise in the treatment of CLL and indolent NHLs. However, a recent study of front-line idelalisib in CLL patients resulted in severe autoimmune toxicities, including transaminitis, pneumonitis and colitis (Lampson et al, 2015) . The combination of rituximab and the Bruton tyrosine kinase inhibitor, ibrutinib, is being studied but results are somewhat disappointing at this point compared to results in CLL (Fowler et al, 2015) .
Bortezomib has been approved by the US Food and Drug Administration for relapsed mantle cell lymphoma and the BBR combination has shown promise in relapsed/refractory mantle cell patients. While not specifically studied here, this regimen is likely to be efficacious in mantle cell lymphoma and should be further tested in treatment-na€ ıve patients.
Further study of this regimen in patients with previously untreated, low grade lymphoma is warranted. Treatment modifications, including the use of subcutaneous bortezomib administration, should be improve tolerability.
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Key Points
• This study showed that the combination of bortezomib, bendamustine and rituximab was well tolerated, produced high overall and complete response rates in a front-line setting.
• Further study of this regimen in patients with previously untreated low-grade lymphoma as well as potentially patients with mantle-cell lymphoma merits further investigation.
